Journal
NANOMEDICINE
Volume 13, Issue 13, Pages 1517-1533Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2017-0393
Keywords
breast cancer; drug resistance; magnetic targeting; nanoparticles; paclitaxel; photodynamic therapy; zinc(II) phthalocyanine
Funding
- Natural Science Foundation of Fujian Province [2015J01348]
- Fundamental Research Funds for the Central Universities [20720170105, 20720162008, 20720172014]
- Training Program of Innovation and Entrepreneurship for Undergraduates [201510384129, 201610384163, 2016Y0426]
- National Natural Science Foundation [31100717, 81772278, 31300285]
- Specialized Research Fund for the Doctoral Program of Higher Education [20110073120072]
- Multidisciplinary Project Cultivation Research Fund of Shanghai Jiao Tong University [YG2012MS10, YG2012MS31]
Ask authors/readers for more resources
Aim: To develop precise targeting and versatile Fe3O4@SiO2-P123/PTX-ZnPc nanoparticles (FSP-PTX-ZnPc NPs) to reverse paclitaxel (PTX)-induced multidrug resistance in breast cancer. Materials & methods: PTX and zinc (II) phthalocyanine (ZnPc) co-loaded FSP-PTX-ZnPc NPs were designed. The resulting multifunctional NPs were evaluated systematically in vitro and in vivo, and the mechanism of drug-resistance reversal was investigated. Results: The NPs enhanced drug uptake in MCF-7/PDR cells by increasing drug solubility and impairing P-glycoprotein efflux. Additionally, magnetic targeting and enhanced permeation and retention (EPR) effect enhanced drug accumulation in tumor, facilitating the chemotherapeutic and photodynamic therapy effects. Moreover, FSP-PTX-ZnPc NPs could penetrate the blood-brain barrier, a desirable trait for brain disease therapy. Conclusion: The multifunctional FSP-PTX-ZnPc NPs are an effective tool for overcoming drug resistance in breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
